Sequana Medical NV (SEQUA) | Stock Overview & Key Data
Sequana Medical NV Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €12.40 on January 4, 2021
Explore how other BE stocks compare to their 52-week ranges: View BE Market 52-Week Insights
Key Statistics
Financial Highlights
Quarter Income Flow
Dec 31, 2018
Annual Income Flow
2024
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sequana Medical NV
SEQUA
|
40.57M Small-cap | 0.00% | 0.00% | 29.79% | 29.79% | 29.79% | 24.49% | 24.49% | 24.49% | 24.49% | 24.49% | 24.49% |
|
Ion Beam
IBAB
|
411.94M Mid-cap | -0.25% | 11.42% | 12.66% | 35.68% | 25.00% | 38.30% | 1.44% | 0.00% | -56.09% | 275.56% | 275.56% |
| N/A | -1.22% | 14.47% | 5.09% | 6.07% | 7.58% | 85.71% | 225.88% | 200.37% | 364.29% | 681.77% | 681.77% | |
|
UCB S.A
UCB
|
50.14B Large-cap | -0.69% | 9.37% | 1.69% | 8.86% | 10.67% | 68.19% | 220.47% | 222.73% | 332.23% | 618.13% | 618.13% |
|
Argenx SE
ARGX
|
41.43B Large-cap | -0.26% | 9.81% | 24.18% | 24.18% | 24.18% | 29.01% | 29.01% | 29.01% | 29.01% | 29.01% | 29.01% |
|
Fagron NV
FAGR
|
1.73B Large-cap | 2.31% | 0.00% | 11.19% | 17.92% | 11.95% | 13.01% | 57.64% | 25.06% | 247.12% | 93.51% | 93.51% |
Ownership & Short Interest
Calculate Your Sequana Medical NV Investment Returns
Long-Term Investment Performance Analysis
Sequana Medical NV stock price in Mar 2026 was €0.49, A €1,000.00 lump sum investment in Sequana Medical NV made 0 years ago would be worth approximately €1,244.90 today, representing a positive return of 24.49%.
2 Months Investment Scenario (Mar 2026 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is SEQUA's 52-week high and low?
- In the last 52 weeks, Sequana Medical NV reached a high of €1.62 (on N/A) and a low of €0.46 (on March 19, 2026).
- What is the market cap and P/E ratio for SEQUA?
- Curious about Sequana Medical NV's size and valuation? Its market capitalization stands at 40.57M. When it comes to valuation, the P/E ratio (trailing twelve months) is -0.46, and the forward P/E (looking ahead) is -4.61.
- Does SEQUA pay dividends? If so, what's the yield?
- As for dividends, Sequana Medical NV isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Sequana Medical NV's main competitors or similar companies to consider before investing?
When looking at Sequana Medical NV, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Ion Beam
IBAB411.94M Healthcare Medical Devices 38.30% 1.44% Financière de Tubize
TUBN/A Healthcare Biotechnology 85.71% 225.88% UCB S.A
UCB50.14B Healthcare Biotechnology 68.19% 220.47% Argenx SE
ARGX41.43B Healthcare Biotechnology 29.01% 29.01% Fagron NV
FAGR1.73B Healthcare Drug Manufacturers - Specialty & Generic 13.01% 57.64% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Sequana Medical NV? (e.g., ROE, Debt/Equity)
- To get a sense of Sequana Medical NV's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 100.62%, the Debt to Equity ratio from the most recent quarter is -1.06, and its Gross Profit Margin stands at 84.98%.
- What is the recent revenue and earnings growth for SEQUA?
- Looking at Sequana Medical NV's growth, its revenue over the trailing twelve months (TTM) was €106K. Compared to the same quarter last year (YoY), quarterly revenue grew by 43.36%, and quarterly earnings saw a YoY growth of N/A.
- How much of SEQUA stock is held by insiders and institutions?
- Wondering who owns Sequana Medical NV stock? Company insiders (like executives and directors) hold about 13.26% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 29.15%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.